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Introduction {#sec001}
============

Comparative genomics have been extensively used to identify DNA copy number variations in cancer. At the chromosomal level, Mertens et al. assessed the distribution of chromosomal gains and losses in published karyotypes from 11 tumour types including 333 cases of colorectal carcinomas (CRCs) \[[@pone.0171690.ref001]\]. In CRC, recurrent gains in chromosomes 7, 8q, 13 and 20; and losses of lp, 5q, 8p, 14p, 17p, 18 and 22 were found \[[@pone.0171690.ref002], [@pone.0171690.ref003]\]. Later, metaphase-based comparative genomic hybridization (m-CGH), a technique of about 5 million bases resolution, was utilized to decipher chromosomal copy number changes in CRC progression. A plethora of studies used m-CGH to identify chromosomal imbalances in CRC, which included gain of chromosomes 1, 13 and 20 and chromosome arms 7p and 8q, whereas chromosome 4 and chromosome arms 8p and 10q were frequently deleted \[[@pone.0171690.ref002]--[@pone.0171690.ref007]\]. However, the large size of genomic aberrations identified by these low resolution techniques, which may contain hundreds of genes, prohibited the precise identification of DNA stretches involved in CRC progression \[[@pone.0171690.ref008]--[@pone.0171690.ref012]\]. In 2004, array-based comparative genomic hybridization (aCGH) emerged as a more promising technology for studying copy number variations at higher resolutions even from formalin-fixed paraffin-embedded (FFPE) archived material \[[@pone.0171690.ref013]--[@pone.0171690.ref017]\]. Bacterial artificial chromosome or BAC-based microarrays have a resolution of 1 million bases, while oligonucleotide-based microarrays have a much higher resolution of 8.9 KB overall median probe spacing (7.4 KB in Refseq genes) with 44,000 to 4.5 million probes dotted on slides, many of which densely cover all known or possible human genes \[[@pone.0171690.ref008]\]. Oligonucleotide-based aCGH is now capable of identifying copy number alterations in few thousands of bases or smaller \[[@pone.0171690.ref018]--[@pone.0171690.ref020]\].

This powerful technology, however, comes with its own limitations. For example, similar or even the same samples performed on different platforms may yield significantly different results. Moreover, the lack of standardized bioinformatic algorithms or analytical methods used to detect genomic aberrations complicates conclusions even further. These are compounded by the inherent heterogeneous nature of cancer evolution \[[@pone.0171690.ref021]\]. Seldom do aCGH-based studies account for such biologically confounding variables. Consequently, previously published colorectal cancer-related aCGH studies have yielded a high level of discordance in the reported genomic aberrations of colorectal cancer \[[@pone.0171690.ref020], [@pone.0171690.ref022], [@pone.0171690.ref023]\]. In addition, traditional means of classifying the importance of cancer-related copy number aberrations (CNAs) include the frequency of their occurrence in different patients. However, cancer genomes are highly complex and frequently harbor random \'passenger\' CNAs that are of no functional significance \[[@pone.0171690.ref024]\]. To alleviate interference from those non-random CNAs, a systematic method, termed Genomic Identification of Significant Targets in Cancer (GISTIC) was recently developed and used in identifying biologically significant CNAs in several cancer types. The GISTIC algorithm determines a \'G\' score based on the frequency and amplitude of the gains and losses. By giving more weight to high copy gains and homozygous losses (amplitude), the GISTIC algorithm argues that such aberrations may be more functionally relevant to the successful evolution of the cancer genome \[[@pone.0171690.ref025]--[@pone.0171690.ref027]\].

Here, we have utilized genomic high-density oligonucleotide-based microarrays to identify CNAs in well-defined colorectal cancers. In addition, we used the GISTIC algorithm to identify \'driver\' chromosomal aberrations in colorectal cancer. We identified 3 distinct CNA patterns in CRCs and show that although CNAs in MSI and MSS CRCs differ with respect to their size, number and chromosomal distribution, the evolutionary and biologically relevant driver mutations of MSI and MSS CRC are not as dissimilar with respect to non-randomcopy number aberrations as traditional methods have previously suggested \[[@pone.0171690.ref015],[@pone.0171690.ref028]\].

Materials and methods {#sec002}
=====================

CRC samples {#sec003}
-----------

A total of 116 CRC patients were recruited for this study. The study's protocols were approved by by the Health Sciences Center (HSC) and Kuwait Institute for Medical Specialization (KIMS) joint committee for the protection of human subjects in research. Written informed consent was obtained from all patients before their inclusion in the study. DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues from 96 patients with sporadic early stage II CRC were used for genomic profiling. Genomic DNA was isolated from microdissected FFPE CRC tissues as described previously \[[@pone.0171690.ref029]\].

aCGH for FFPE samples {#sec004}
---------------------

### a. Labeling of genomic DNA {#sec005}

Human Genome CGH Microarray 244A slides (Agilent Technologies, CA, USA) were used for FFPE extracted DNA samples. We followed the protocol described in \[[@pone.0171690.ref030], [@pone.0171690.ref031]\]. A total of 2.5 μg sex matched control DNA (Promega, WI, USA) was fragmented by sonication. The FFPE DNA was fragmented only if there was any large molecular weight DNA. About 500 ng of the fragmented samples were then run on 1.5% agarose gel for 1 hour to check the extent of fragmentation of the DNA. Once fragmentation was deemed appropriate, 2 μg of the control DNA was labeled with Cy3 (Agilent technologies, CA, USA) and 2μg of FFPE DNA with Cy5 (Agilent technologies, CA, USA) for 30 minutes at 85°C. After labeling the DNA was purified using KREA pure columns (Agilent technologies, CA, USA). The samples were then measured on a Nanodrop and Degree of Labeling (DOL) was calculated according to the following formula; $$Degree\ of\ Labeling = \left( {340\ x\ pmol/\mu l\ of\ dye} \right)/\left( {ng/l\mu\ of\ Genomic\ DNA\ x\ 1000} \right)$$

The samples were hybridized onto microarray slides only if the DOL was between 1.5--2.5%.

### b. Hybridization of labeled DNA {#sec006}

Appropriate volumes of Human Cot-I DNA (Invitrogen, CA, USA), 10X Blocking Agent (Agilent Technologies) and 2X Hybridization buffer (Agilent Technologies) were added to the paired Cy5 and Cy3 labeled DNA and the hybridization mix was mixed by pipetting gently. The Hybridization cocktail was then incubated at 95°C for 3 minutes, then immediately followed by 30 minutes at 37°C. The tubes were spun to collect the samples and an appropriate volume of Agilent-CGH block buffer (Agilent technologies, CA, USA) was added to the hybridization cocktail. The samples were mixed gently and centrifuged for collection. We dispensed 490 μl of the hybridization cocktail onto a clean gasket slide, which was already placed into a hybridization chamber. A microarray slide was placed active side down onto the gasket. The chamber was assembled and incubated in the hybridization rotating oven (Agilent technologies, CA, USA) for 40 hours at 60°C and 20 rpm.

### c. Washing of the microarray slide {#sec007}

The hybridization chamber was disassembled carefully and the microarray slide sandwich was completely submerged into wash buffer 1 (Agilent technologies, CA, USA) at room temperature. The slides were then gently pried open using a pair of forceps and the gasket was allowed to drop to the bottom of the jar. The microarray slide was quickly transferred to a slide rack submerged in wash buffer 1 and incubated for 5 minutes. Then the rack was transferred to the next dish containing wash buffer 2 (Agilent technologies, CA, USA) at 37°C for 1 minute. The slide rack was then transferred to a dish containing Acetonitrile for 1 minute followed by 30 seconds in Stabilization solution (Agilent technologies). The rack was removed carefully in order to minimize the number of droplets on the slide. The slides were scanned immediately on an Agilent scanner.

### d. Data analysis of the sample {#sec008}

Scanned images were imported; background subtracted and normalized using Feature extraction software version 10.7.1.1 (Agilent Technologies, CA, USA). The feature extraction software generates a quality Control Report which helps determine the quality of the aCGH. Quality Control metrics such as derivative of log ratio spread (DLRS), background noise (BG noise), signal intensity, reproducibility and signal to noise ratio are generated in the QC report.DLR Spread is defined as the spread of the Log Ratio differences between consecutive probes along all chromosomes. It is the most important metric as it gives us the ability to measure noise of the log ratio independent from the number and severity of aberrations found, making it instrumental in assessing the overall quality of each microarray experiment. If the DLR Spread value was higher than 0.5, the cases were excluded from further analysis. The text files representing data ratio points log2 of test/control ratios were imported to Nexus software (Biodiscovery, CA, U.S.A). Quality values ranged between 0.05--0.4, which are excellent values given the degraded nature of the samples. To minimize false positive calls and random CNV variations, Fast Adaptive State Segmentation Technique (FASST2) with a stringent significance threshold of 5.0E-6 was used to determine copy number aberrations. Moreover, we utilized two algorithms to more accurately reflect functional CNVs and separate them from bystander genomic aberrations. The first termed Significance Testing for Aberrant Copy number (STAC) algorithm, and the second is a systematic method termed Genomic Identification of Significant Targets in Cancer (GISTIC) o identify biologically significant copy number aberrations in these samples. Both algorithms were calculated using Nexus software version 8 (Biodiscovery, El Segundo CA, USA)

Multiplex Ligation-dependent Probe Amplification (MLPA) {#sec009}
-------------------------------------------------------

DNA was diluted to a working stock concentration of 50 ng/μl. A total of 250 ng (5μl) of DNA was aliquoted into sterile 0.2 ml tubes and denatured and then cooled to 25°C in a thermal cycler. A master mix containing hybridization components supplied as part of the kit (SALSA MLPA probemix P294-B1 Tumour-Loss from MRC Holland, Amsterdam, Netherlands) was prepared and added to the samples at 25°C and the reaction was mixed by pipetting. The hybridization reaction was carried out according to the manufacturer's instructions and the samples were incubated overnight at 60°C. A ligase buffer mix was prepared with reagents supplied with the kit and ligation was carried out with Liagse-65. Following ligation, a PCR master mix was prepared using SALSA PCR reagents from the kit and PCR reaction was carried out by mixing 10μl of ligation product with the PCR master mix in new tubes at temperatures recommended in the protocol. All reactions were carried according to manufacturer's protocol. The amplified PCR product was mixed with formamide, CEQ-600 marker, and 3μl of this MLPA PCR sample was then added to each well of a 96 well plate and a drop of mineral oil was added on top. Fragment separation was carried out by loading the plate into the CEQ8000 Genetic Analysis System according to manufacturer's protocol. CSV files generated from these runs were then imported into the Coffalyser Software (MRC Holland, Amsterdam, Netherlands) for MLPA analysis.

MSI fragment analysis {#sec010}
---------------------

DNA was extracted from 116 macro-dissected colorectal tumors and MSI fragment analysis was performed on them and their matching normal using MSI analysis system version 1.2 kit (Promega Corporation, WI, USA). Powerplex Matrix Standards 3100/3130 kit (Promega Corporation, WI, USA) was used to perform spectral calibration of the Applied Biosystems 3130 Genetic Analyzer. The system allowed co-amplification of a total of seven markers including mononucleotide repeat markers (Bat-25, BAT-26, NR-21, NR-24 and MONO-27) and pentanucleotide repeat markers (Penta C and Penta D). MSI status was determined using the mononucleotide markers by comparing results from tumor and its matching normal, a cancer was classified as MSS when no length variations were detected between the samples for all the markers. The cancer was classified as MSI-high when 2 or more markers showed length variations between the tumors sample and its matching normal. We further classified each cancer into MSI or MSS subclasses by analyzing the expression of MLH1, MSH2, PMS2 and MSH6 using immunohistochemistry. Statistical correlation was performed for samples were both methods were used to determine MSI status.

Results and discussion {#sec011}
======================

Genetic aberration in colorectal cancer detected using high resolution oligo-microarrays {#sec012}
----------------------------------------------------------------------------------------

We have performed aCGH on a total of 150 cases of CRC out of which 116 yielded acceptable DLR Spread value below 0.5 and were utilized for further analysis. [Table 1](#pone.0171690.t001){ref-type="table"} shows the clinical characteristics of the cases that were utilized for aCGH analysis.

10.1371/journal.pone.0171690.t001

###### An overview of the clinical characteristics of the patients used in this study.

![](pone.0171690.t001){#pone.0171690.t001g}

  Patients' characteristics   Number (Percentage)
  --------------------------- ---------------------
  Number of patients          
      Sex                     116 (100)
      Male                    57 (49)
      Female                  59 (51)
  Localization                
      Right                   28 (24.1)
      Left                    47 (40.5)
      Rectum                  23 (19.8)
      Colon unspecified       18 (15.5)
  T-stage                     
      T-3                     62 (53.4)
      T-4                     25 (21.6)
      Unknown                 29 (25.0)
  Differentiation             
      Well                    13 (11.2)
      Moderate                84 (72.4)
      Poor                    11 (9.5)
      Unknown                 8 (6.9)
  Dukes' stage                
      Dukes' B                96 (82.8)
      Dukes' C                18 (15.5)
      Dukes' D                2 (1.7)
  Follow-up                   
      Relapsed Metastasis     11 (9.5)
      Local                   13 (11.2)
  Disease Free                73 (62.9)
  Unknown                     19 (16.4)
  MSI Status                  
      MSI                     18 (15.5)
      MSS                     90 (77.6)
      Unknown                 8 (6.9)
  Nationality                 
      West Asian              37 (31.9)
      European                79 (68.1)

The resultant aCGH profiles showed many chromosomal gains and deletions. The most frequent chromosomes involved in copy number gains in colorectal cancer were: Chromosomes 7 (56%), 8q (56%), 13 (61%), and 20 (79%). Chromosomal losses most frequently involved were chromosome arm 1p (71%), 8p (72%), 17p (55%), 22q (60%) and chromosomes 14 (77%), 15 (66%) and 18 (80%) ([Fig 1](#pone.0171690.g001){ref-type="fig"}). This data is consistent with previously published data from our and other groups \[[@pone.0171690.ref028]--[@pone.0171690.ref034]\]. However, these data represent a summation of all aberrations involved in colorectal cancer regardless of the type, stage, location and other molecular characteristics that may have a significant impact on the aCGH data obtained. Next, we subdivided this heterogeneous colorectal cancer set into genetically and phenotypically well-characterized sets and analyzed the copy number aberrations for each set using the GISTIC algorithm to obtain a functional list of genes involved in the aberrations within different subsets. It is worthy to note that our cohort was selectively biased towards TNM stage II (Dukes\' B). Therefore, the frequencies of MSI and stage do not reflect population incidence. Microsatellite instability data was successfully obtained from 108 of 116 CRC cases (93%). [Table 2](#pone.0171690.t002){ref-type="table"} shows the clinico-pathological characteristics of MSS and MSI CRC cases. As expected, most MSI cases were associated with poor cancer differentiation and right sidedness.

![Representative karyotype colorectal cancer as determined by the Agilent Human Genome CGH Microarray 244A platform, showing summary results for those chromosome gains/losses more frequently detected in all colorectal cancer samples analyzed (n = 116).\
The red regions indicate loss while the green signify chromosomal gains.](pone.0171690.g001){#pone.0171690.g001}

10.1371/journal.pone.0171690.t002

###### Association between clinic-pathological characteristics and MSI status.

![](pone.0171690.t002){#pone.0171690.t002g}

                        No. of Samples   MSS        MSI    p-Value   
  --------------------- ---------------- ---------- ------ --------- ------
  **Gender**                             0.44                        
  Female                54               46         51.7   8         42.1
  Male                  54               43         48.3   11        57.9
  Total                 108              89         100    19        100
  **Localization**                       \<0.0001                    
  Left                  39               38         51.4   1         6.7
  Right                 26               13         17.8   13        81.3
  Rectum                20               20         27     0         0
  Transverse            4                2          2.7    2         13.3
  Total                 89               73         100    16        100
  **T-stage**                            0.417                       
  T-3                   56               50         72.5   6         60
  T-4                   23               19         27.5   4         40
  Total                 79               69         100    10        100
  **Differentiation**                    \<0.0001                    
  Poor                  11               4          4.8    7         38.9
  Moderate              79               68         81     11        61.1
  Well                  12               12         14.3   0         0
  Total                 102              84         100    18        100
  **Dukes' Stage**                       0.65                        
  Dukes' B              89               74         83.1   15        78.9
  Dukes' C              17               13         14.6   4         21.1
  Dukes' D              2                2          2.2    0         0
  Total                 108              89         100    19        100
  **Follow Up**                          0.27                        
  Relapse Metastatic    9                9          11.7   0         0
  Local                 12               11         14.3   1         7.1
  Disease Free          70               57         74     13        92.9
  Total                 91               77         100    14        100

Genomic landscape patterns in MSI and MSS CRC {#sec013}
---------------------------------------------

Subdivision of aCGH profiles was performed to delineate distinct CNAs pertinent to the evolution of gentically and phenotypically distinct CRC subsets. Microarray data revealed 3 distinct patterns of genomic aberrations in CRC ([Table 3](#pone.0171690.t003){ref-type="table"}). Pattern 1, characterized by small-sized and few gains and losses copy number alterations, was observed in 52.6% of MSI cases, and in 10.1% of MSS cases ([Fig 2A](#pone.0171690.g002){ref-type="fig"}). CRC with Pattern 2, on the contrary, have numerous losses and gains that cyclically alternate resembling a pattern previously described in solid tumors termed Chromothripsis \[[@pone.0171690.ref025]--[@pone.0171690.ref038]\]. Recently, using genome-wide long mate-pair sequencing and SNP microarray of CRC and their metastases, chromothripsis rearrangements have been found to occur frequently in CRC \[[@pone.0171690.ref039]--[@pone.0171690.ref041]\]. Since aCGH can only detect copy number alterations, and only that, we are not sure that these rearrangements represent true chromothripsis events. We, therefore, will refer to this pattern as chromothripsis-like or alternating copy state ([Fig 2B](#pone.0171690.g002){ref-type="fig"}). Chromothripsis-like events were observed in 31.6% of MSI CRC cases. In MSS CRC cases, chromothripsis-like events were uncommon and documented in only 10% of the cases. This data indicated that chromothripsis-like events were more significantly associated with MSI than MSS genotypes (p = 0.024). Pattern 3, exemplified by large sized gains and losses, which may span chromosomal arms or whole chromosomes ([Fig 2C](#pone.0171690.g002){ref-type="fig"}) were found in 15.8% of MSI CRC cases. As expected, this particular pattern was the most common in the genomic landscape of MSS CRC cases (89.9%).

![Patterns of genomic aberrations highlighted by high-resolution aCGH in CRC.\
a) Shows pattern 1 from 3 patients as examples (upper 22 autosomes). The zoomed inset focused on an area of chromosome arm 3P with 2 small deletions. b) Shows 4 cases of CRC with pattern 2. Notice the large number of small aberrations that alternate between gain-baseline-loss. Insets show zoomed in picture of chromosome 7 from one patients (upper panels) and chromosome 1 from a different case. Notice how well-demarcated and clear are these alternating aberrations. c) Shows a case with pattern 3, which involves copy number alterations of chromosomal arms or whole chromosomes (Insets). In all figures deletions are shown in red and deviate below the 0 (log2 ratio) and gains are depicted in blue.](pone.0171690.g002){#pone.0171690.g002}

10.1371/journal.pone.0171690.t003

###### Number of aberrations among different patterns of genomic instability.

![](pone.0171690.t003){#pone.0171690.t003g}

                                  N            Mean number of aberrations   Std. Error   95% Confidence Interval for Mean   Minimum   Maximum   
  --------------- --------------- ------------ ---------------------------- ------------ ---------------------------------- --------- --------- -----
  Copy gain       MSS Pattern 3   80           95.90                        7.945        80.09                              111.71    0         358
  MSI_Pattern 1   10              34.40        11.736                       7.85         60.95                              4         118       
  MSI_Pattern 2   6               341.83       51.592                       209.21       474.45                             125       458       
  MSI_pattern 3   3               102.00       30.265                       28.22        232.22                             44        146       
  MSS_Pattern 2   9               501.78       63.395                       355.59       647.97                             202       867       
  Total           108             137.86       14.647                       108.82       166.90                             0         867       
  Anova p value                   **0.0001**                                                                                                    
  Copy loss       MSS Pattern 3   80           115.01                       9.900        95.31                              134.72    4         431
  MSI_Pattern 1   10              23.50        4.636                        13.01        33.99                              5         56        
  MSI_Pattern 2   6               277.33       60.759                       121.15       433.52                             96        521       
  MSI_pattern 3   3               63.33        20.301                       24.01        150.68                             36        103       
  MSS_Pattern 2   9               410.44       60.956                       269.88       551.01                             123       607       
  Total           108             138.74       13.079                       112.81       164.67                             4         607       
  Anova p value                   **0.0001**                                                                                                    

Enumeration of genomic aberrations in MSI and MSS CRC {#sec014}
-----------------------------------------------------

It is widely accepted that MSS CRC have higher number and larger-sized genomic aberrations compared to MSI CRC. Nevertheless, seldom do researchers divide the genomic profiles obtained by microarrays or other advanced methodologies into patterns before comparing aberration frequencies and sizes between the two groups. [Fig 3](#pone.0171690.g003){ref-type="fig"} shows the frequencies of total aberrations in different classes and patterns of CRC. [Table 3](#pone.0171690.t003){ref-type="table"} subdivides these aberrations into losses and gains. As shown, the mean number of autosomal genomic aberrations in MSS CRC was 217.5 (95% C.I: 186--249), which was significantly higher than MSI CRC with pattern 1 (mean of 60 and 95% C.I: 26--95; p\<0.0001) but equivalent to MSI CRC with pattern 3 genomic aberrations (mean of 170 and 95% C.I: 9.8--331.5; p\>0.05). However, MSI CRC with pattern 2 had significantly more cumulative genomic aberrations than MSS CRC (mean of 624 and 95% C.I: 355--894; p\<0.0001). Similarly, MSS CRC with pattern 2 had the highest number of genomic aberration ([Table 3](#pone.0171690.t003){ref-type="table"}).

![Aberrational frequencies in MSS (a) and MSI (b) CRC. The aberrational length X-axis in a and b are log transformed, with median shown as solid line and mean as dashed line. c) Shows the average number of genomic aberrations per patient in MSI and MSS CRC.](pone.0171690.g003){#pone.0171690.g003}

We next assessed and compared the length of genomic aberrations in MSS and MSI CRC. [Fig 3](#pone.0171690.g003){ref-type="fig"} shows the histogram spread of genomic aberration sizes with the indicated median and mean length in MSS ([Fig 3A](#pone.0171690.g003){ref-type="fig"}) and MSI ([Fig 3B](#pone.0171690.g003){ref-type="fig"}) CRC. On average, patients with MSI CRC had smaller sized genomic aberrations compared to MSS CRC patients ([Fig 3C](#pone.0171690.g003){ref-type="fig"}).

Unsupervised clustering of genomic aberrations in CRC {#sec015}
-----------------------------------------------------

We employed unsupervised complete Linkage Hierarchical clustering on the 116 CRC cases. The method orders cases based solely on their genomic aberrations without prior knowledge of other clinical, genetic or MMR data. [Fig 4A](#pone.0171690.g004){ref-type="fig"} shows the 5 clusters generated from this analysis. The CNAs of each group/cluster are shown in [Fig 4B](#pone.0171690.g004){ref-type="fig"}. Cluster 1 (group 1) identified genomic aberrations significantly associated with MSS CRC harboring largely wild type *BRAF*, and were left-sided with rectosigmoidal subsite enrichment ([Table 4](#pone.0171690.t004){ref-type="table"}).

![a) Complete Linkage Hierarchical clustering of 116 cases with CRC. The generated 5-clusters are depicted in the dendogram. The lower panels show microsatellite stability and BRAF gene status. b) Frequency (aggregate) histograms from 5-groups of CRCs clustered according to copy number aberration patterns. The upper histogram represents the summation of all the aberrations in 116 cases of CRC. Deviations up from 0% (Log2 ratio) represent copy number gains and are colored blue, while deviations below the 0% line (red) represent copy number losses. The y-axis represents % of samples with a specific aberration. The two horizontal lines demarcate the cutoff (35%) used to call aberrations in the STAC algorithm. The lower histograms are aberrations found in the 5 generated clusters.](pone.0171690.g004){#pone.0171690.g004}

10.1371/journal.pone.0171690.t004

###### Clinicopathological characteristics of the 5-clusters generated by unsupervised complete Linkage Hierarchical clustering.

![](pone.0171690.t004){#pone.0171690.t004g}

                                 Group 1          Group 2         Group 3    Group 4   Group 5    
  ------------------------------ ---------------- --------------- ---------- --------- ---------- -----------
  **Clinical characteristics**                                                                    
  **Microsatellite**                                                                              
  Stable (MSS) n = 89            81(1.2×10^−6^)   6               1          1         0          
  Instable (MSI) n = 19          6                7(0.003)        2(0.06)    1         3(0.003)   p0.00013
  MMR unknown n = 8              6                2                                               
  **BRAF mutation**                                                                               
  Negative n = 103               88(5.1×10^−4^)   8               3          2         2          
  Positive n = 13                5                7(1.5×10^−4^)   0          0         1          p\<0.0001
  KRAS mutation                                                                                   
  Negative n = 88                75(0.0188)       7               2          2         2          
  Positive n = 20                16               2               1          0         1          
  **CRC site**                                                                                    
  Left n = 67                    62(1.1×10^−4^)   4               0          1         0          
  Right n = 31                   17               8(0.018)        2          1         3(0.018)   0.003
  **CRC subsite**                                                                                 
  Rectum n = 23                  21               2               0          0         0          
  Rectosigmoid n = 13            13(0.047)        0               0          0         0          
  Descending/Sigmoid n = 28      25               2               0          1         0          
  Transverse colon n = 4         2                1               0          0         1          
  Ascending n = 13               6                5(0.003)        0          0         2(0.019)   
  Caecum n = 14                  9                2               2(0.038)   1         0          
  **Survival**                                                                                    
  Disease-recurrence n = 24      23(0.022)        0               0          0         1          0.18
  Disease-free n = 63            51               7               1          2         2          

We next employed a global frequency statistical approach using the significance testing for aberrant copy number (STAC) algorithm. STAC-based algorithm is a robust method which identifies a set of aberrations that are stacked on top of each other from different patients or microarrays such that it would not occur by chance. To find these events, aberrations (usually narrow regions) are permuted in each arm of each chromosome and assess how likely it is for an event to occur at any location at a particular frequency set here at 35% and minimum p\<0.05 \[[@pone.0171690.ref039]\]. Cluster 1, grouped samples with broad high frequency gains in chromosome arms 20q (58--97%, p\<0.0001), 13q (63--71%, p\<0.0001), 7 (41--63%, p\<0.0001), 8q (45--62%, p\<0.0001), and broad losses in chromosomes 18 (76--91%, p\<0.0001), 14q (45--84%, p\<0.0001), 8p (65--82%, p\<0.0001), 15q (54--76%, p\<0.0001), and 1 (35--76%, p\<0.0001). Cluster 2, identified cases with MSI, which also harbored *BRAF* V600E mutation, were significantly associated with right-sidedness and ascending colon subsite enriched ([Table 4](#pone.0171690.t004){ref-type="table"}). This cluster had low frequency gains and losses stretching along the genome, with specific and significant peaks of gains at chromosome arms 1q 23.3 (40%, p\<0.0001), 11q11 (40%, p\<0.0001), 12q24.31 (40%, p\<0.001), 13q14.12--14.13 (40%, p\<0.005), and losses at chromosome arms 14q11.2 (60%, p\<0.0001), 22q11.23 (53%, p\<0.0001), 6q21.32 (47%, p\<0.0001), 14q32.33 (40%, p\<0.01), 16p13.2 (40%, p\<0.0001), 8p23.3, 8p23.1,18q12.2 and 18q23 (40%, p\<0.02). The other clusters, namely clusters 3, 4 and 5, aggregated small number of cases and exhibited similar characteristics to group 2 ([Table 4](#pone.0171690.t004){ref-type="table"}). Group5, specifically, was similar to group 2, while group 3 was enriched with cecal cancers.

Genomic aberrations in MSI and MSS CRC using supervised clustering analysis {#sec016}
---------------------------------------------------------------------------

Genetic aberrations generated by Supervised clustering from well-defined sets of samples, in this case 19 and 89 cases of MSI and MSS CRC respectively, are shown in ([Fig 5A](#pone.0171690.g005){ref-type="fig"}). Consistent with unsupervised clustering, the genomic aberration profiles of MSS and MSI CRC were largely identical to group 1 and group 2 respectively ([Fig 5A](#pone.0171690.g005){ref-type="fig"}). Direct comparison of the generated genomic profiles between MSS and MSI CRC, highlighted the extensive differences in genomic aberrations between the two groups ([Fig 5B](#pone.0171690.g005){ref-type="fig"}). Chromosome arms 1p, 8p, 10q, 17p and chromosomes 4, 14, 15, 18 deletions were significantly more frequent in MSS than MSI CRC ([Table 5](#pone.0171690.t005){ref-type="table"}). Similarly, chromosome arms 7p, 8q, 12q, 20q and chromosome 13 gains were more frequent in MSS compared to MSI CRC ([Fig 5B](#pone.0171690.g005){ref-type="fig"} and [Table 6](#pone.0171690.t006){ref-type="table"}). Other small aberrations on chromosomes 3p, 5, 21 and 22 were interesting. For example, the 3p small deletion was a common event (33%) in our CRC cases ([Fig 5A and 5B](#pone.0171690.g005){ref-type="fig"}). The deletions were well demarcated around exon 5 of the *FHIT* gene and appeared in both MSS and MSI CRC, although more significantly deleted in MSI cancers ([Fig 5B](#pone.0171690.g005){ref-type="fig"}). *FHIT* gene deletion and its reduced expression have been reported before in association with MSI CRC by our group \[[@pone.0171690.ref042]\].

![Genomic aberrational differences between MSS and MSI CRC.\
a) Shows histogram profiles of the autosome from 19 MSI and 89 MSS CRC. Deviations up from 0% represent copy number gains and are colored blue, while deviations below the 0% line represent copy number losses and are colored red. b) Genomic aberrations frequency (or %) differences between MSS and MSI CRC. The significant differences are displayed as bars in the significance row marked with black arrow. Blue bars deviating below 0% indicates significantly more frequent gains in MSS compared to MSI CRC, while blue bars deviating above 0% represent more frequent gains in MSI compared to MSS (e.g. chromosome arm 12q). Similarly, red bars deviating above 0% indicates significantly more frequent losses in MSS compared to MSI CRC, while red bars deviating below 0% represent more frequent losses in MSI compared to MSS (e.g. chromosome 3p).](pone.0171690.g005){#pone.0171690.g005}

10.1371/journal.pone.0171690.t005

###### Copy number aberrations generated by the GISTIC algorithm in MSS CRC.

![](pone.0171690.t005){#pone.0171690.t005g}

  Narrow Region[\*](#t005fn001){ref-type="table-fn"}   Extended Region                  Type   Q-Bound     G-Score
  ---------------------------------------------------- -------------------------------- ------ ----------- ---------
  chr22:22,669,244--22,674,560                         chr22:22,669,244--22,686,007     Loss   2.54E-10    61.1
  chr6:32,563,052--32,576,786                          chr6:32,563,052--32,603,160      Loss   2.54E-10    58.3
  chr4:69,305,945--69,550,743                          chr4:69,295,525--69,550,743      Loss   2.54E-10    56.7
  chr20:47,701,770--47,747,973                         chr20:47,664,076--49,743,884     Gain   3.06E-10    55.6
  chr8:39,386,202--39,461,142                          chr8:39,365,809--39,496,849      Loss   2.54E-10    48.9
  chr18:74,434,936--74,528,730                         chr18:72,984,865--76,117,153     Loss   2.54E-10    41.0
  chr13:72,532,072--72,545,802                         chr13:72,468,464--72,879,517     Gain   3.06E-10    34.1
  chr15:19,938,622--19,973,512                         chr15:19,884,805--19,973,512     Loss   2.54E-10    33.9
  chr3:163,992,380--164,107,362                        chr3:163,992,380--164,107,362    Loss   2.54E-10    33.7
  chr14:105,283,523--105,311,171                       chr14:105,151,893--105,479,165   Loss   2.54E-10    32.1
  chr20:25,853,011--25,926,849                         chr20:25,830,521--27,100,000     Gain   3.06E-10    31.8
  chr8:39,373,309--39,485,162                          chr8:39,373,309--39,491,113      Gain   3.06E-10    30.7
  chr8:126,438,529--126,498,088                        chr8:123,842,688--126,506,271    Gain   3.06E-10    29.6
  chr1:149,376,254--149,397,162                        chr1:149,367,733--149,397,162    Loss   2.54E-10    28.7
  chr1:18,205,194--18,286,328                          chr1:18,197,094--18,317,078      Loss   2.54E-10    28.6
  chr8:1,059,261--1,099,327                            chr8:0--1,321,118                Loss   2.54E-10    28.0
  chr17:11,096,055--11,171,903                         chr17:9,647,537--13,915,524      Loss   2.54E-10    26.8
  chr7:27,449,750--27,595,647                          chr7:26,477,611--30,369,308      Gain   3.06E-10    25.3
  chr16:6,504,522--6,512,278                           chr16:6,443,207--6,531,574       Loss   2.54E-10    24.6
  chr11:55,191,165--55,197,896                         chr11:55,191,165--55,216,250     Loss   2.54E-10    23.8
  chr11:55,131,937--55,191,165                         chr11:55,115,301--55,191,165     Gain   6.85E-10    23.5
  chr5:180,359,104--180,364,172                        chr5:180,268,615--180,364,172    Loss   2.54E-10    22.9
  chr7:75,046,728--75,065,482                          chr7:73,034,227--75,365,689      Gain   3.91E-09    22.4
  chr6:162,739,756--162,757,660                        chr6:162,543,026--163,000,404    Loss   2.54E-10    22.1
  chr20:14,855,016--14,880,574                         chr20:14,752,042--14,916,356     Loss   2.61E-10    21.7
  chr4:1,372,689--1,433,700                            chr4:979,401--1,522,379          Loss   2.61E-10    21.6
  chr2:132,598,122--132,890,744                        chr2:132,598,122--132,900,372    Gain   2.26E-07    20.2
  chr19:18,362,768--18,392,988                         chr19:17,152,138--18,542,288     Gain   6.37E-07    19.6
  chr21:46,806,563--46,851,646                         chr21:46,023,979--46,851,646     Loss   6.36E-09    19.1
  chr17:41,572,059--41,640,287                         chr17:41,497,558--41,672,900     Gain   3.17E-06    18.6
  chr1:146,605,059--146,672,075                        chr1:146,605,059--146,686,184    Gain   4.87E-06    18.3
  chr12:15,738,418--15,751,788                         chr12:15,710,138--15,827,008     Gain   6.97E-06    18.1
  chr10:38,700,181--39,018,864                         chr10:38,700,181--39,018,864     Gain   8.02E-06    18.0
  chr16:29,840,265--29,885,801                         chr16:29,566,294--30,389,686     Gain   1.51E-05    17.6
  chr19:53,811,858--53,897,694                         chr19:53,290,145--54,363,641     Gain   2.01E-05    17.4
  chr21:9,896,630--10,038,957                          chr21:9,896,630--10,065,864      Gain   2.05E-05    17.4
  chr10:134,586,239--134,803,162                       chr10:134,298,652--134,938,121   Loss   3.91E-07    17.2
  chr6:26,352,706--26,361,349                          chr6:26,256,770--26,720,741      Gain   4.04E-05    16.9
  chr14:19,417,751--19,449,642                         chr14:19,278,801--19,493,856     Loss   1.51E-06    16.6
  chr12:130,314,128--130,348,539                       chr12:130,249,201--130,408,894   Loss   1.77E-06    16.5
  chr9:45,357,769--45,739,136                          chr9:45,357,769--45,739,136      Gain   1.12E-04    16.2
  chr1:145,917,263--146,000,447                        chr1:145,885,332--146,000,447    Loss   2.83E-05    15.1
  chr3:163,992,380--164,107,362                        chr3:163,992,380--164,107,362    Gain   0.0012065   14.5
  chr3:60,454,798--60,465,650                          chr3:60,383,448--60,485,055      Loss   1.04E-04    14.4
  chr9:135,119,951--135,258,527                        chr9:134,748,046--135,386,643    Loss   1.59E-04    14.1
  chr4:69,218,552--69,295,525                          chr4:69,127,903--69,295,525      Gain   0.0032968   13.8
  chr22:47,396,201--47,433,182                         chr22:47,327,520--47,701,683     Loss   5.73E-04    13.4
  chr9:40,501,951--41,897,530                          chr9:39,152,128--41,897,530      Loss   5.92E-04    13.4
  chr11:131,509,992--131,674,900                       chr11:131,491,803--133,419,821   Loss   7.30E-04    13.3
  chr1:0--738,061                                      chr1:0--738,061                  Gain   0.0068923   13.2
  chr22:22,717,333--22,722,828                         chr22:22,717,333--22,722,828     Gain   0.0082828   13.0
  chr5:732,646--742,598                                chr5:0--754,698                  Loss   0.0020752   12.7
  chr16:67,887,820--68,061,099                         chr16:65,245,773--68,673,221     Gain   0.0157484   12.5
  chr6:29,956,856--30,007,461                          chr6:29,956,856--30,016,093      Loss   0.0030972   12.4
  chr10:1,207,969--1,325,890                           chr10:0--3,675,211               Loss   0.0039758   12.2
  chr2:61,332,414--61,586,388                          chr2:61,102,731--65,541,488      Gain   0.0241268   12.1
  chr16:54,349,083--54,384,952                         chr16:54,349,083--54,384,952     Loss   0.0060993   12.0
  chr9:42,913,008--43,080,383                          chr9:42,913,008--43,080,383      Loss   0.0063739   11.9
  chr18:1,610,018--1,759,320                           chr18:917,185--2,088,004         Loss   0.0082034   11.8
  chr4:191,070,477--191,128,555                        chr4:191,054,399--191,128,555    Loss   0.0094985   11.7
  chr15:94,744,405--94,838,744                         chr15:92,681,164--96,935,377     Loss   0.0395216   10.7
  chr11:5,740,514--5,764,428                           chr11:4,333,855--6,580,666       Loss   0.0395216   10.7

\*Shaded rows identify regions common to MSI CRC.

10.1371/journal.pone.0171690.t006

###### Copy number aberrations generated by the GISTIC algorithm in MSI CRC.

![](pone.0171690.t006){#pone.0171690.t006g}

  Narrow Region[\*](#t006fn001){ref-type="table-fn"}   Extended Region                  Type   Q-Bound    G-Score
  ---------------------------------------------------- -------------------------------- ------ ---------- ---------
  chr6:32,576,786--32,603,160                          chr6:32,563,052--32,644,260      Loss   4.82E-12   12.7
  chr8:39,349,089--39,359,852                          chr8:39,349,089--39,365,809      Loss   8.29E-09   10.7
  chr22:22,669,244--22,717,333                         chr22:22,645,114--22,722,828     Loss   1.42E-06   8.5
  chr14:19,487,351--19,493,856                         chr14:18,753,436--19,493,856     Loss   5.47E-06   7.9
  chr1:149,367,733--149,397,162                        chr1:149,367,733--149,397,162    Loss   6.95E-06   7.8
  chr1:193,475,381--193,529,957                        chr1:193,456,932--193,544,824    Loss   4.26E-05   7.2
  chr14:105,589,128--105,636,720                       chr14:105,589,128--105,636,720   Loss   4.26E-05   7.2
  chr11:55,115,301--55,191,165                         chr11:55,115,301--55,216,250     Gain   0.002372   7.1
  chr15:19,501,226--19,796,337                         chr15:19,351,570--20,150,205     Loss   4.26E-05   7.1
  chr3:60,339,210--60,409,611                          chr3:60,339,210--60,731,181      Loss   1.92E-04   6.6
  chr8:7,258,853--7,953,633                            chr8:267,005--8,144,283          Loss   2.44E-04   6.5
  chr6:245,716--327,686                                chr6:245,716--327,686            Loss   5.65E-04   6.0
  chr4:69,295,525--69,550,743                          chr4:69,127,903--69,550,743      Loss   0.001436   5.5
  chr1:18,197,094--18,292,586                          chr1:18,175,101--18,292,586      Loss   0.001436   5.5
  chr18:33,269,571--33,343,946                         chr18:31,514,045--42,919,686     Loss   0.00465    4.8
  chr11:134,210,403--134,452,384                       chr11:133,657,612--134,452,384   Loss   0.011382   4.4
  chr16:54,349,083--54,384,952                         chr16:52,708,563--54,384,952     Loss   0.012709   4.3
  chr21:13,591,226--14,355,692                         chr21:13,572,244--14,355,692     Loss   0.015794   4.1
  chr12:130,314,128--130,408,894                       chr12:129,946,814--130,706,577   Loss   0.018008   4.1
  chr7:141,962,422--141,981,657                        chr7:141,148,142--158,628,139    Loss   0.019226   4.0
  chr9:42,913,008--43,080,383                          chr9:42,913,008--43,080,383      Loss   0.019226   4.0
  chr20:57,698,990--57,804,320                         chr20:57,664,611--57,848,527     Loss   0.027869   3.8
  chr11:5,735,996--5,764,428                           chr11:4,455,169--6,584,397       Loss   0.035934   3.7
  chr16:34,318,531--34,455,993                         chr16:34,148,509--35,005,009     Loss   0.040215   3.7
  chr22:46,946,978--47,684,217                         chr22:46,946,978--47,900,828     Loss   0.049436   3.5

\*Shaded rows point to deletions private to MSI and not identified by the GISTIC algorithm as significant in the MSS CRC series.

Functional relevance of genomic aberrations in MSS and MSI CRC {#sec017}
--------------------------------------------------------------

It is well accepted that CNA in cancer involves many random genetic events that frequently distort and may conceal the important genomic aberrational events that are functionally relevant. Our classical comparison of the frequencies of genetic events between MSS and MSI CRC cases highlighted the extensive and widespread differences in genomic aberrations between the two groups ([Fig 5B](#pone.0171690.g005){ref-type="fig"}). However, how \'genomically\' close or apart are MSS and MSI CRC in terms of functional or driver mutations, is a question that has not been well-addressed before. Therefore, we next reanalyzed the 108 dataset using 2 independent algorithms that focus on the functional relevance of a particular genomic aberration. First, we used STAC algorithm approach to identify statistically significant and recurrent genomic CNAs within subsets of samples under the same settings mentioned above. The second algorithm GISTIC, which identifies functionally significant CNAs by giving more weight to high copy gains and homozygous losses (amplitudes), which may be functionally relevant to the successful evolution of the cancer genome \[[@pone.0171690.ref027]\]. Such permutations are not considered in the STAC analysis we used. Therefore, the two methods may be considered complementary rather than comparable.

[Fig 6](#pone.0171690.g006){ref-type="fig"} shows functionally significant CNAs generated by the STAC algorithm in MSI and MSS CRC. The peaks identify aberrations that are significantly recurrent. As demonstrated before with the traditional frequency-based method, that MSS CRC accumulated more CNAs than MSI CRC, albeit, more functionally relevant here. A remarkable observation that emanated from the use of the STAC algorithm was the high-degree of similarity between the functionally-relevant copy number alterations in MSI and MSS CRC. On almost all the autosomes, functionally significant CNAs found in MSI CRC mapped precisely onto those found in MSS CRC ([Fig 6](#pone.0171690.g006){ref-type="fig"}). All genomic aberrations specific to MSI CRC are highlighted with arrows in [Fig 6](#pone.0171690.g006){ref-type="fig"}. These aberrations did not reach the 35% cutoff, or did not contain functional genes (chromosome 4) and therefore excluded by the algorithm.

![Frequency profiles of copy number aberrations from 89 MSS (middle histogram; with gains above 0% line shown as blue peaks and below 0% as deletions in red) and 19 MSI CRC cases (divided histogram; upper showing gains in blue and lower histogram shows deletions in red).\
The vertical grey lines indicate significant peaks of copy number alterations. Notice how these peaks align precisely in both MSS and MSI CRC. Copy number aberrations that are private for MSI CRC cases are marked with red arrows for deletions and blue arrows for amplifications. Below each red arrow are the corresponding chromosomal region ideogram and a zoomed histogram focused on the red arrowed region. The histograms show deletions in red and amplifications in blue and significant STAC-generated peaks in grey as stated above. Deletions marked with asterisks correspond to the deletions marked with the red arrows. All these aberrations are not considered in the exported regions because they do not reach the 35% cutoff value (marked horizontal black lines on chromosome 9). Note how the marked FHIT deletion crosses the 35% line. The individual copy number alteration for each patient from 19 MSI cases are shown as small vertical red and blue bars indicating deletions and amplifications respectively. Note how well-demarcated are these recurrent aberrations.](pone.0171690.g006){#pone.0171690.g006}

We next employed the GISTIC algorithm on the same data set. [Fig 7](#pone.0171690.g007){ref-type="fig"} shows the significant CNAs in both MSS ([Fig 7A](#pone.0171690.g007){ref-type="fig"}) and MSI ([Fig 7B](#pone.0171690.g007){ref-type="fig"}) as broad and narrow regions represented by vertical grey lines. Again, these functionally significant aberrations were more common in MSS compared to MSI CRC cases (Tables [5](#pone.0171690.t005){ref-type="table"} and [6](#pone.0171690.t006){ref-type="table"}). Genes involved in cellular senescence, S-phase control of the cell cycle, histone H4-K5 acetylation, nucleosome assembly and telomere maintenance were among the top 10 most significant GO-functions identified.

![GISTIC analysis of MSS and MSI CRC copy number aberrations.\
a) Histogram profile of the autosome from 89 MSS and b) from 19 MSI CRC. Deviations up from 0% represent copy number gains and are colored blue, while deviations below the 0% line represent copy number losses and are colored red. Vertical grey lines indicate regions identified as significant using the Q-Bound (p\>0.05) and G-score\>1. Asterisks, pinpoint narrow GISTIC regions identified only in MSI CRC cases. c) Zoomed in view of the regions private to MSI CRC showing the corresponding chromosome ideogram on top and focused GISTIC-identified areas with broad (grey) and narrow (dark grey) zones along the histograms (middle) and the 19 patients (lower panels), each represented in a horizontal line indicating the deletions in red, homozygous deletions in dark red/broad red lines and amplifications in blue.](pone.0171690.g007){#pone.0171690.g007}

Deletions were the most overwhelming functional aberrations identified by the GISTIC algorithm in MSI CRC ([Fig 7B](#pone.0171690.g007){ref-type="fig"}). As proposed by the STAC algorithm, the GISTIC-generated regions in MSI corresponded precisely to regions on the MSS histogram ([Fig 7](#pone.0171690.g007){ref-type="fig"} and [Table 5](#pone.0171690.t005){ref-type="table"}). However, GISTIC analysis identified 8 narrow autosomal regions specific to MSI CRC ([Fig 7B and 7C](#pone.0171690.g007){ref-type="fig"} and [Table 6](#pone.0171690.t006){ref-type="table"}).

Our STAC profiling suggests, with the exception of 8 private genomic copy alterations identified by the GISTIC algorithm, that MSI and MSS CRC functional CNAs are similar. These shared genomic events may be key in the evolution of both types of CRC. These reserved CNAs might be critical to the oncogenesis in primary cellular transformation stages, later distinct CNAs specific to MSI and MSS might occur due to the influence of specific tumor microenvironments. For example, it has been shown that MSI distinct CNAs include immune related genes that alters their susceptibility to the immune system, hence MSI CRC's favorable prognosis \[[@pone.0171690.ref043]--[@pone.0171690.ref044]\]. Regardless of the mechanism of how such similarities in CNAs are attained in these two distinct groups, our data argue that, at least at the genomic copy number level, the evolutionary and biologically relevant driver mutations of MSI CRC are a subset of those found in MSS CRC, and that the two groups are not as dissimilar with respect to functional CNAs as traditional methods have previously suggested. We next tested this notion using MLPA tumor-loss panel (P294-A1), which profiles 20 key tumor suppressor genes that are frequently deleted in cancer with 50 probes spanning different exons of the corresponding genes. Due to the limited tissues available to us, MLPA was performed on microdissected DNA extracted from 44 cases (subset of 116 cases, used for aCGH). The MMR status was known for 40 cases (MSI n = 7 and MSS n = 33). [Fig 8](#pone.0171690.g008){ref-type="fig"} shows the normalized copy number ratios for the 20 tumor suppressor genes distributed according to MMR status. The data show loss of 7 tumor suppressor genes in this cohort; *CHD5*, *FHIT*, *TSC1* (exon 7), *PTEN*, *NF1*, *SMAD4* (exon 5), and *SMARCB1* (exon 9) irrespective of the MMR status ([Fig 8](#pone.0171690.g008){ref-type="fig"}).

![Normalized gene dosage levels (Y-axis) for 20 tumor suppressor genes (X-axis) generated using MLPA.\
Asterisks indicate deleted genes/exons.](pone.0171690.g008){#pone.0171690.g008}

The genomic aberrations detected in MSS and MSI may have a direct effect on genes' expression, which are thought to be the driving force of disease pathology of both types of tumors as suggested previously by several groups \[[@pone.0171690.ref045]--[@pone.0171690.ref048]\]. Kheurekseid et al., (2013) identified a comprehensive list of genes showing clear differential expression patterns in CRC. Most of these genes are located in genomic regions well affected by the aberrations found in our study. Unfortunately, we were limited by the use of FFPE tissues to pursue each of the genes located within the CNAs identified. Understanding the molecular impact of these expression alterations would provide a better understanding of the molecular pathology of CRC. Localizing the culprit genes involved in CNAs can also serve as molecular markers to aid in diagnosis, follow up and most importantly potential development of individualized therapeutic strategies. This study therefore was limited in its approach and may benefit from a direct correlation between genes located within the CNAs and their expression. Nevertheless, this study illuminated genomic deletions as a possible mechanism for loss or reduced expression of the 7 tumor suppressor genes regardless of the MMR status. The *FHIT* gene deletion was identified previously by us and others as a mechanism for the reduced FHIT protein expression in CRC \[[@pone.0171690.ref042],[@pone.0171690.ref049]\]. The tumor suppressors TSC1 and PTEN protein expression were shown to be reduced in CRC compared to normal tissues or adenomas \[[@pone.0171690.ref050],[@pone.0171690.ref051]\]. Similarly, SMAD4 and SMARCB1 expression were absent/reduced in 64% \[[@pone.0171690.ref052]\], 67% \[[@pone.0171690.ref053]\] of CRC respectively. Interestingly, CHD5 protein expression was repressed in the majority of adenomas via genetic deletion, hypermethylation or by microRNA-211 suppression \[[@pone.0171690.ref054],[@pone.0171690.ref055]\]. Our study is supportive of genomic deletions as partly the reason behind the lack or reduced expression of these tumor suppressor genes in CRC regardless of the MMR status.

Conclusion {#sec018}
----------

The last decade witnessed a substantial increase in our understanding of the genomic landscape of CRC. The use of low resolution genome-profiling technologies, like BAC-microarrays to identify copy number differences between MSS and MSI CRCs propagated the notion that these two subtypes of CRC are substantially different at the copy number level. Our high resolution genetic profiling of CRC supports this genomic heterogeneity between MSS and MSI CRC. For example, MSS-CRC had more numerous larger aberrations while MSI-CRC had smaller-sized aberrations. Moreover, there were distinct patterns of genomic aberrations in CRC, one of which, pattern 2 (chromothripsis-like) was significantly enriched in MSI CRC, while MSS CRC was significantly associated with Pattern 3 (loss/gain of whole chromosomes or chromosome arms). In fact, the examination of the genomic histograms showed significant differences between MSI and MSS as previously reported. However, closer inspection of the patterns generated suggests that, although there were unique copy number differences, MSI and MSS CRC functional copy number aberrations are similar. These shared genomic events could highlight key events in the evolution of both types of CRC. This finding supports the hypothesis that driver mutations incurred by CNAs in MSI CRC are also found in MSS CRC, and that the two groups are not as dissimilar in respect to CRC development. Our results suggest that MSI and MSS copy number aberrations driving CRC development may be functionally comparable.
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aCGH

:   Array-based comparative genomic hybridization

BAC

:   Bacterial artificial chromosome

mCGH

:   Metaphase-based comparative genomic hybridization

CNA

:   Copy number aberration

MSS

:   Microsatellite Stable

STAC

:   Significance testing for aberrant copy number

GISTIC

:   Genomic Identification of Significant Targets in Cancer

CRC

:   Colorectal Carcinomas

MSI

:   Microsatellite Instability

MLPA

:   Multiplex Ligation-dependent Probe Amplification

FFPE

:   Formalin-fixed paraffin-embedded

DLRS

:   Derivative of log ratio spread

FASST

:   Fast Adaptive State Segmentation Technique

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** HA FA.**Data curation:** HA FA AA.**Formal analysis:** HA FA.**Funding acquisition:** FA.**Investigation:** HA MM.**Methodology:** HA FA.**Project administration:** HA FA.**Resources:** HA FA.**Software:** HA FA.**Supervision:** MB FA.**Validation:** MB.**Visualization:** AA.**Writing -- original draft:** HA FA.**Writing -- review & editing:** HA.
